Oscar Health (NYSE: OSCR) backs 2026 outlook at Raymond James event

Rhea-AI Filing Summary

Oscar Health, Inc. is confirming that its previously issued full-year 2026 financial guidance remains in place as it participates in the 2026 Raymond James Institutional Investors Conference on March 2, 2026. The guidance being reaffirmed was first provided in its February 10, 2026 press release covering fourth-quarter and full-year 2025 results.

The company also reminds readers that these expectations are forward-looking statements subject to risks and uncertainties described in its Annual Report on Form 10-K for the year ended December 31, 2025 and other SEC filings.

0001568651FALSE00015686512026-03-022026-03-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 2, 2026

Oscar Health, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-40154

46-1315570

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

75 Varick Street, 5th Floor

New York, New York 10013

(Address of Principal Executive Offices) (Zip Code)

(646) 403-3677

(Registrant’s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbols

Name of each exchange on which registered

Class A Common Stock, $0.00001 par value per share

OSCR

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Oscar Health, Inc. (the “Company”) will participate in the 2026 Raymond James Institutional Investors Conference (the “Conference”) on March 2, 2026. At the Conference, the Company will reaffirm the full year 2026 guidance that it provided in its financial results press release for the fourth quarter and full-year 2025, dated February 10, 2026.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward- looking statements. These statements include, but are not limited to, statements about our expected financial performance and upcoming events and presentations. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control. Although management believes that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”), and our other filings with the SEC. You are cautioned not to place undue reliance on any forward-looking statements made herein. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward- looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Oscar Health, Inc.
			By:						/s/ Adam McAnaney
			Name:						Adam McAnaney
			Title:						Chief Legal Officer

Date: March 2, 2026

FAQ

What did Oscar Health (OSCR) announce in this 8-K?

Oscar Health announced that it is reaffirming its full-year 2026 financial guidance. The company confirmed this outlook while participating in the 2026 Raymond James Institutional Investors Conference, referencing guidance originally issued with its fourth quarter and full-year 2025 results on February 10, 2026.

Which guidance is Oscar Health (OSCR) reaffirming for 2026?

Oscar Health is reaffirming the full-year 2026 guidance it previously provided. That guidance was first shared in a February 10, 2026 press release covering fourth-quarter and full-year 2025 results, and the company states that this outlook remains unchanged as of the conference date.

What event is linked to Oscar Health’s 2026 guidance reaffirmation?

Oscar Health tied its 2026 guidance reaffirmation to participation in the 2026 Raymond James Institutional Investors Conference on March 2, 2026. During this event, the company stated that its previously issued full-year 2026 financial outlook from February 10, 2026 continues to apply.

Does Oscar Health consider these 2026 guidance statements forward-looking?

Yes. Oscar Health characterizes its 2026 guidance and related expectations as forward-looking statements. It notes these are not guarantees of future performance and are subject to risks and uncertainties, including those discussed under “Risk Factors” in its Form 10-K for 2025 and other SEC filings.

Where can investors find the risks related to Oscar Health’s 2026 outlook?

Investors are directed to the “Risk Factors” section of Oscar Health’s Annual Report on Form 10-K for the year ended December 31, 2025. The company also points to its other SEC filings for additional information that could cause actual results to differ from the reaffirmed 2026 guidance.

Is Oscar Health obligated to update its 2026 guidance after this reaffirmation?

Oscar Health states it does not undertake an obligation to publicly update or revise its forward-looking statements, including 2026 guidance, except as required by law. It emphasizes that each forward-looking statement speaks only as of the date on which it is made.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB